| 000 | 01924nam a22003017a 4500 | ||
|---|---|---|---|
| 008 | 211101s20212021 xxu||||| |||| 00| 0 eng d | ||
| 022 | _a2589-9775 | ||
| 040 | _aOvid MEDLINE(R) | ||
| 099 | _a34365935 | ||
| 245 | _aClinical Efficacy of Remdesivir and Favipiravir in the Treatment of Covid-19 Patients: Scenario So Far. | ||
| 251 | _aCurrent Drug Research Reviews. 2021 Aug 06 | ||
| 252 | _aCurr Drug Res Rev. 2021 Aug 06 | ||
| 253 | _aCurrent drug research reviews | ||
| 260 | _c2021 | ||
| 260 | _fFY2022 | ||
| 265 | _saheadofprint | ||
| 266 | _d2021-11-01 | ||
| 520 | _aThe novel SARS-CoV-2 is a new disease that has caused severe destruction to human lives across the globe, including infection, mortality and financial crises, for which, scientific researchers have been directed towards the development of treatment and controlling measures against coronavirus. Currently, there has been no approved drug for the treatment of the disease, but several antiviral drugs have shown therapeutic effects from which, remdesivir and favipiravir are two such drugs. These drugs have shown some therapeutic potential in the treatment of COVID-19 by inhibiting viral enzyme RNA-dependent RNA polymerase. The purpose of this systematic review is to provide an overview of the effectiveness of these two drugs based on the clinical trials reported in current published data. Copyright(c) Bentham Science Publishers; For any queries, please email at [email protected]. | ||
| 546 | _aEnglish | ||
| 650 | _aIN PROCESS -- NOT YET INDEXED | ||
| 651 | _aMedStar Southern Maryland Hospital Center | ||
| 656 | _aHospitalist | ||
| 657 | _aJournal Article | ||
| 700 | _aChidurala, Ram Mohan | ||
| 790 | _aBhatti K, Chidurala RM, Das R, Mehta DK, Rana M, Saini M | ||
| 856 |
_uhttps://dx.doi.org/10.2174/2589977513666210806122901 _zhttps://dx.doi.org/10.2174/2589977513666210806122901 |
||
| 942 |
_cART _dArticle |
||
| 999 |
_c6808 _d6808 |
||